» Articles » PMID: 9783886

Oxygenation Predicts Radiation Response and Survival in Patients with Cervix Cancer

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 1998 Oct 23
PMID 9783886
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Hypoxia appears to be an important factor in predicting tumor relapse following radiation therapy. This study measured oxygenation prior to treatment in patients with cervix cancer using a polarographic oxygen electrode to determine if oxygenation was an important prognostic factor with regard to tumor control and survival.

Materials And Methods: Between May 1994 and June 1997, 74 eligible patients with cervix cancer were entered into an ongoing prospective study of tumor oxygenation prior to primary radiation therapy. All patients were evaluated with an Eppendorf oxygen electrode during examination under anesthesia. Oxygenation data are presented as the hypoxic proportion, defined as the percentage of pO2 readings of <5 mm Hg (abbreviated as HP5).

Results: The HP5 ranged from 2 to 99% with a median of 52%. With a median follow-up of 1.2 years, the disease-free survival (DFS) rate was 69% for patients with HP5 of < or =50% compared with 34% for those with HP5 of >50% (log-rank P = 0.02). Tumor size above and below the median of 5 cm was also significantly related to DFS (P = 0.0003) and patients with bulky hypoxic tumors had a significantly lower DFS (12% at 2 years) than either bulky oxygenated or non-bulky oxygenated or hypoxic tumors (65%, P = 0.0001).

Conclusions: Hypoxia and tumor size are significant adverse prognostic factors in a univariate analysis of disease-free survival in patients with cervix cancer. A high risk group of patients with bulky hypoxic tumors have a significantly higher probability of relapse and death.

Citing Articles

Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention.

Bylicky M, Shankavaram U, Aryankalayil M, Chopra S, Naz S, Sowers A Mol Cancer Ther. 2024; 23(4):577-588.

PMID: 38359816 PMC: 10985469. DOI: 10.1158/1535-7163.MCT-23-0796.


Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study.

Okamura A, Watanabe M, Okui J, Matsuda S, Takemura R, Kawakubo H Ann Surg Oncol. 2023; 30(9):5885-5894.

PMID: 37264286 DOI: 10.1245/s10434-023-13686-y.


Fluorinated carbohydrates for F-positron emission tomography (PET).

Campbell E, Jordan C, Gilmour R Chem Soc Rev. 2023; 52(11):3599-3626.

PMID: 37171037 PMC: 10243284. DOI: 10.1039/d3cs00037k.


Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.

Okamura A, Watanabe M, Okui J, Matsuda S, Takemura R, Kawakubo H Ann Surg Oncol. 2022; 30(4):2176-2185.

PMID: 36528742 DOI: 10.1245/s10434-022-12960-9.


The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Gallez B Front Pharmacol. 2022; 13:853568.

PMID: 35910347 PMC: 9335493. DOI: 10.3389/fphar.2022.853568.